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Treatment of bipolar disorder with lithium therapy during pregnancy is a medical challenge. Bipolar disorder is more prevalent in
women and its onset is often concurrent with peak reproductive age. Treatment typically involves administration of the element
lithium, which has been classiﬁed as a class D drug (legal to use during pregnancy, but may cause birth defects) and is one of only
thirtyknownteratogenicdrugs.Thereisnoclearrecommendationintheliteratureonthemaximumacceptabledosageregimenfor
pregnant, bipolar women. We recommend a maximum dosage regimen based on a physiologically based pharmacokinetic (PBPK)
model. The model simulates the concentration of lithium in the organs and tissues of a pregnant woman and her fetus. First, we
modeled time-dependent lithium concentration proﬁles resulting from lithium therapy known to have caused birth defects. Next,
we identiﬁed maximum and average fetal lithium concentrations during treatment. Then, we developed a lithium therapy regimen
to maximize the concentration of lithium in the mother’s brain, while maintaining the fetal concentration low enough to reduce
the risk of birth defects. This maximum dosage regimen suggested by the model was 400mg lithium three times per day.
1.Introduction
Bipolar disorder, which aﬀects approximately 1% of the pop-
ulation (mostly women), is a type of mood disorder which
has periods of manic behavior and periods of depressive
behavior. An overly joyful or overexcited state characterizes
manic behavior; extremely sad and hopeless states char-
acterize depressive behavior [1]. A standard treatment for
bipolardisorderinvolvestreatmentwiththeelementlithium,
which was the ﬁrst mood-stabilizing medication approved
for treatment of “mania,” which later came to be known as
bipolar disorder, in 1970 [2]. The brand names of bipolar
lithium treatment drugs are Eskalith and Lithobid, which
deliver lithium as lithium carbonate (Li2CO3). The typical
size of a dose of lithium drug ranges from 900 to 1800mg
Li2CO3/day (if administered in 2 divided doses a day) and
900 to 2400mg Li2CO3/day (if administered in 3-4 divided
doses a day) [3]. Although the mechanism by which lithium
mitigates the symptoms of bipolar disorder is not completely
understood, lithium is thought to aﬀect sodium transfer
in the brain [4]. High doses can cause lithium poisoning
and side eﬀects such as the inability to control movement,
blackouts, seizures, hallucinations, severe headaches, and
acute renal failure [3, 5].
In women, bipolar disorder typically manifests prior to
the age of 30, which coincides with the timing of a woman’s
peak reproduction age [4]. Unfortunately, lithium is also
classiﬁed as one of only thirty known teratogenic drugs (i.e.,
substances associated with causing birth defects) [6]. There-
fore, the treatment of pregnant women for bipolar disorder
with lithium presents a major risk for the safety of the fetus.
Lithium crosses the human placenta freely [2]a n da ﬀects
vasculature formation in the fetus [4]. Because the majority
ofvasculatureformsduringtheﬁrsttrimester,lithiumaﬀects
the development of the fetus most in the ﬁrst trimester [7].
The most common birth defects associated with 30 babies
exposed to lithium during pregnancy were hypotonia (43%);
cardiac problems (40%); respiratory distress syndrome and
cyanosis (30%); poor feeding ability, lethargy, and depressed
Moro and suck reﬂexes (27%) [2].
Although lithium treatment concurrent with pregnancy
has the potential to cause serious birth defects, there is little2 Advances in Bioinformatics
guidance toward appropriate lithium treatment regimens
for pregnant women. Current FDA-approved packaging for
Lithobidstates,“Ifthisdrugisusedinwomenofchildbearing
potential, or during pregnancy, or if a patient becomes
pregnant while taking this drug, the patient should be
apprised by their physician of the potential hazard to the
fetus” [8]. The extent of the current guidance by physicians
is to avoid lithium if possible during the ﬁrst trimester of
pregnancy; if this is not possible, and during the second and
third trimesters, the lowest eﬀective dose of lithium should
be used [3].
It would be beneﬁcial to quantitatively establish a
maximum acceptable dosage regimen that will not cause
teratogenic eﬀects on the fetus. However, measuring the
actual concentration in the fetus is prohibitively diﬃcult and
has a potential to cause damage to the fetus. Furthermore,
a large dataset associating actually administered lithium
therapy regimens correlated with instances and noninstances
o fb i r t hd e f e c t sw o u l db er e q u i r e di no r d e rt oc o n c l u s i v e l y
establish a correlation of lithium exposure with birth defect
incidence; this data is not currently available. Additionally,
animalmodelsdescribingfetallithiumtoxicityorteratogenic
eﬀects are lacking.
In lieu of these experimental methods, lithium con-
centration in various organs can be predicted by the
construction of a pharmacokinetic model, such as that
presented by Bischoﬀ et al. [9] ;t h i sp r o v i d e sam e a n st o
predictlithiumconcentrationwithinthefetusduringvarious
dosage regimens based upon the concentrations in other
parts of the mother’s body which are easier and safer to
sample.Bymodelingtheeﬀectofdosageregimenspreviously
associated with high incidence of birth defects, improved
dosage regimens with lower likelihoods of causing birth
defects can be proposed. To this end, we have employed a
modiﬁed version of the biological model ﬁrst proposed by
Bischoﬀetal.[9](thePhysiologicallyBasedPharmacokinetic
(PBPK) model). PBPK models have been developed and
validated for a variety of applications since they were ﬁrst
introduced, including predicting organophosphate insecti-
cide concentration in humans [10], modeling toxicology of
complex mixtures [11], and drug discovery [12]. This work
applies a modiﬁed PBPK model to the problem of impaired
fetal development due to maternal lithium treatment in
order to propose maximum recommended dosage regimens.
2.BasisandDevelopment ofModel
2.1. General Assumptions of the Model. Af e wa s s u m p -
tions and features of this model warrant discussion. First,
this mass-transfer-based model includes organ “compart-
ments”; each compartment represents a “lumped” region
of organs/tissues with similar physiochemical properties. All
properties of the “compartment” (volume, blood ﬂow rate,
etc.) have independently veriﬁable anatomical signiﬁcance
[13]. Another assumption employed in the model develop-
ment was an assumption of ﬂow-limited conditions; this
implies that the blood leaving a tissue/organ is in diﬀusion
equilibrium with the tissue/organ, such that the perfusion
rate is rate controlling rather than the diﬀusion rate. The
rationale and justiﬁcation for this assumption is discussed
in detail in Bischoﬀ et al. [13]. Finally, in this model, each
compartment is modeled as a continuously stirred tank
reactor (CSTR), with constant volume, constant inﬂow and
outﬂowrates,andabloodpermeablepartitioningmembrane
through which lithium enters the organ/tissue along with the
blood. Each organ/tissue has a speciﬁc membrane partition
constant to characterize the relative partitioning of the
drug between the blood, which delivers the drug, and the
tissue; this parameter can also be described as the tissue
to plasma equilibrium distribution ratio. These values are
contained in Table 1. These distribution ratios were found
from published literature for all compartments except the
fetus, for which data was not available. In addition, there is
no published literature that provides absolute fetal lithium
concentrations associated with lithium therapy regimens.
However, dosage regimens which have resulted in birth
defects have been documented [2]. Without a correlation
of fetal concentrations to these known pathological dosage
regimens,thevalueofthefetalcompartmentpartitioncoeﬃ-
cient(RF)canbechosenarbitrarily;thisallowedustoexplore
the eﬀect of diﬀerent lithium therapy regimens on relative
fetal concentration. Since the fetal lithium concentrations
reported by the simulation are relative to pathological cases,
any value chosen for RF will simply give scaled results leading
to the same conclusions. This makes selecting a particular
value for RF arbitrary. We selected a value of 0.8 as the fetal
partition coeﬃc i e n tt ou s ei no u rm o d e l .
The original model of Bischoﬀ et al. [9] predicted con-
centrations of the anticancer drug methotrexate in diﬀerent
organs in the body. Because methotrexate is metabolized
in the liver and secreted through the colon without a
concentration buildup in the upper organs, Bischoﬀ et al.
[9] modeled only the lower organs in the body. Our model,
however, deals with lithium, for which the brain is a primary
siteoflithiumactivityandaccumulation.Furthermore,aswe
are speciﬁcally modeling the lithium exposure of pregnant
women, the fetus and the uterus are additional physiolog-
ical regions for which lithium concentrations should be
predicted. Therefore, we have modiﬁed the original PBPK
model to better reﬂect our system by adding compartments
for the brain, the uterus, and the fetus, and modifying the
compartment connectivity accordingly (see Figure 1). In our
model, we assumed that the fetus was in the ﬁrst trimester,
whenlithiumexposureismostdamagingtoitsdevelopment.
Due to the lower development of the fetus at this point in the
pregnancy, we modeled the fetus as a single compartment.
Our model also included thyroid, gastrointestinal (GI) tract,
kidneys, and bone compartments.
2.2. Physiological Considerations of the Model. In order to
investigate the eﬀect of lithium dosage regimens on maternal
organ and fetal concentrations, data on lithium partition-
ing between blood plasma and the relevant organs and
tissues is required. This enables the model to predict
which organs/tissues preferentially uptake and concentrate
lithium. We obtained partitioning coeﬃcients directly fromAdvances in Bioinformatics 3
Table 1: Model parameters.
Conversion factor for
lithium content of drug
dose
8/300 mEq (mmol) Li/mg dose [3]
Bone mass 8 kg [14]
Bone density 1.1 g/mL [15]
Kidney clearance rate (kk)2 0 m L / m i n [ 3]
Physiological volumes of organ/tissue compartments
Plasma (VP) 5200 mL [16]
Bone (VB) 7273 mL Calculated from bone
mass and bone density
Kidney (VK) 280 mL [16]
Uterus (VU) 1000 mL [7]
Gastrointestinal (GI) tract
(VG) 1650 mL [16]
Thyroid (VT)1 3 m L [ 16]
Brain (VBr) 1450 mL [16]
Fetus, 1st Trimester (VF) 150 mL [7]
Blood ﬂow to organs
Bone (QB) 272 mL/min
Calculated from bone
perfusion and bone mass
[14]
Kidney (QK) 1240 mL/min [16]
Uterus (QU) 475 mL/min [7]
GI Tract (QG) 1100 mL/min [16]
Thyroid (QT) 60 mL/min Modeled based on
similar sized organs
Brain (QBr) 700 mL/min [16]
Fetus, 1st trimester (QF) 300 mL/min [7]
Tissue to plasma equilibrium distribution ratios for lithium
Bone (RB)1 . 5 [ 3]
Kidney (RK)1 [ 3]
Uterus (RU)0 . 4 [ 3]
GI Tract (RG)1 [ 3]
Thyroid (RT)1 . 5 [ 3]
Brain (RBr)1 . 5 [ 3]
Fetus (RF)0 . 8 Estimated; see rationale
in text
the medical database Lexi-Comp Online [3] for all organs
except the fetus, for which data was not available. The
kidneys are the main source of lithium clearance from
the body; approximately 99% of the lithium in the body
is removed through the urine, while the remaining 1%
passes through feces. Therefore this model assumes that the
lithium clearance through the feces is negligible and only
considers kidney clearance for lithium removal. The GI tract
is included because an oral mode of delivery is employed
forlithium-containingbipolardrugs,thuslithiumisingested
and absorbed through the GI tract.
Lexi-Comp Online indicated that lithium accumulates in
the brain, thyroid, and bone tissue. Therefore, these organs
have the possibility to signiﬁcantly aﬀect the concentrations
inimportantorgansbyabsorbingamajorityoflithiumwhen
blood plasma concentrations are high or releasing lithium
even when blood plasma concentrations are low.
The connectivity of the model, as shown in Figure 1,i s
based on clinical physiology. Each compartment represents
an organ with a certain partition coeﬃcient, denoted by a
dashed line, through which blood ﬂows. The box marked
“Plasma” can be viewed as the aorta, or the main pathway
for blood ﬂow through the body; within the aorta, mixing
of the blood/plasma is assumed to occur so that the blood
exiting this compartment, destined to the other organs of
the body, has a single concentration at any point in time
(CP).Theplasmasplitsintotwopathways;theupperpathway
proceeds to the thyroid and brain, while the lower pathway
proceeds to the GI tract, kidneys, uterus, and bone. As in the
body, blood ﬂows through these organs in parallel. Since the4 Advances in Bioinformatics
Brain
Thyroid
Plasma
GI tract
Kidney
Uterus
Fetus
Bone
Urine
QBr
QT
QG
QK
QU
QF
QB
Figure 1: Connectivity diagram for the relevant organs of the
PBPK model for lithium accumulation in a pregnant woman.
Each compartment represents an organ with a certain partition
coeﬃcient, denoted by a dashed line, through which blood ﬂows.
fetus is connected to the mother through the uterus, the ﬂow
of blood to and from the fetus travels through the uterus.
According to Kozma [2], lithium crosses the human placenta
freely, and the concentrations in fetal serum are equal to
that of maternal serum; this enables us to assume that the
concentration of lithium in the blood passing entering the
fetus has the same concentration as that of the blood leaving
the uterus. Because our model assumes a fetus in the ﬁrst
trimester, the renal system was assumed to be immature
such that renal clearance of lithium from the fetus would be
negligible [2]. Therefore the only route for lithium to exit
the fetus is partitioning back from the fetus to the plasma.
Thishastheadditionaleﬀectofcausingadelayedclearanceof
lithium from the fetus (and accumulation of lithium within
the fetus), so that toxic levels of lithium may be experienced
by the fetus even though the concentration of lithium for the
mother may be within the therapeutic range [2].
2.3. Mathematical Considerations of the Model-Coupled Dif-
ferential Equations. The following coupled diﬀerential equa-
tions describe the time dependence of lithium concentra-
tions in the compartments from Figure 1.B a s e du p o na
general mass balance, the rate of accumulation of lithium
((d/dt)(ViCi)) within the control volume (Vi)o fag e n e r a l
physiological compartment i is equal to the rate of lithium
entering the compartment minus the rate of lithium leaving
the compartment minus the rate of lithium clearance from
the system plus the rate of lithium absorption to the system,
as shown in (1).
General organ/tissue mass balance:
d
dt
(ViCi) = rLi,entering −rLi,exiting −rLi,clearance +rLi,absorption
(1)
For a general compartment i (exceptions are discussed
below), the rate of lithium entering the compartment is the
productoftheplasmaﬂowratetothecompartment(Qi)and
the concentration of lithium in the plasma (CP); the rate of
lithium leaving a general compartment is the product of the
plasma ﬂow out of the compartment (which is equivalent
to the ﬂow in, Qi) and the concentration of lithium in the
blood ﬂowing out. The concentrationof lithium in theblood
exiting an organ will be a function of the concentration
of lithium in the organ (Ci) divided by the partitioning
coeﬃcient Ri that characterizes the distribution of lithium
between the plasma and the organ/tissue. The mass of
lithium leaving the organ is often lower than entering due to
the tissue to plasma equilibrium distribution ratio, resulting
in lithium accumulation in that tissue. For all organs (except
the kidneys), the rate of lithium clearance within the organ is
negligible, and the only mode of lithium removal is through
partitioning of lithium back from the tissue to the blood.
Therefore, the general mass balance presented above in (1)
can be modiﬁed with these described adjustments, resulting
in the following.
General compartment mass balance without clearance or
absorption:
d
dt
(ViCi) = QiCP −Qi
Ci
Ri
(2)
Assuming that the volume of each compartment is constant,
the time-dependent concentration of lithium in the general
tissue compartment i can be expressed as follows.
Constant-volume compartment mass balance without clear-
ance or absorption:
dCi
dt
= Qi

CP −
Ci
Ri

1
Vi
(3)
This general form applies to the brain, the thyroid, and
the bone; the diﬀerential equations characterizing lithium
concentration in these compartments are described in (4),
(5), and (6)b e l o w .
Brain (brain compartment mass balance):
dCBr
dt
= QBr

CP −
CBr
RBr

1
VBr
(4)
Thyroid (thyroid compartment mass balance):
dCT
dt
= QT

CP −
CT
RT

1
VT
(5)Advances in Bioinformatics 5
Bone (bone compartment mass balance):
dCB
dt
= QB

CP −
CB
RB

1
VB
(6)
The connectivity between the uterus and the fetus, the
clearance of lithium from the kidneys, the absorption of
lithium into the gut, and the contribution of all tissues
to the plasma concentration lead to additional terms in
the diﬀerential equations for these compartments; further
discussion is provided below for each compartment with a
form modiﬁed from the general one provided above in (3).
Uterus (uterus compartment mass balance):
dCU
dt
=

QU

CP −
CU
RU

+QF

CF
RF
−
CU
RU

1
VU
(7)
Blood ﬂow to the uterus comes from both the plasma
compartment (at ﬂow rate QU and at the plasma lithium
concentration CP)a sw e l la sf r o mt h ef e t u sc o m p a r t m e n t
(at ﬂow rate QF and at the lithium concentration leaving the
fetus, CF/RF), and so there are two inﬂow terms in the uterus
mass balance, as can be seen in (7). Furthermore, the ﬂow
exitingtheuterusisatalithiumconcentrationofCU/RU,and
it exits at ﬂow rate QF (to the fetus) and at ﬂow rate QU (back
to the plasma compartment), providing two outﬂow terms
to the uterus compartment mass balance.
Fetus (fetus compartment mass balance):
dCF
dt
= QF

CU
RU
−
CF
RF

1
VF
(8)
Because the fetus is connected through the body only
through the uterus, and not directly to the plasma compart-
ment, the blood entering and leaving the fetus passes ﬁrst
through the uterus, as shown above in (8). The partition
function for the fetus, RF, also describes the partitioning
between the fetus compartment and the plasma.
Kidneys (kidney compartment mass balance):
dCK
dt
=

QK

CP −
CK
RK

− kk
CK
RK

1
VK
(9)
In the kidney compartment mass balance (9), the term kk
refers to the kidney clearance rate (Table 1). The term kk ∗
CK/RK gives the rate at which lithium is cleared from the
body through the kidneys.
GI tract (GI tract compartment mass balance):
dCG
dt
=

QG

CP −
CG
RG

+G(t)

1
VG
(10)
The parameter G(t) is the rate (mEq/minute) of lithium
absorption into the blood through the GI tract. In this study,
we assumed all lithium drug was delivered orally as a time-
release capsule. This term is only nonzero during the release
of lithium from an active drug dosing time period. Assuming
that the time-release format of the drug delivery would result
in a constant rate of absorption over the course of the drug
dissolution time, the absorption term G(t)i n( 10)a b o v ew a s
calculated as follows.
Drug absorption term:
G(t) =
mD

mEq Li/mg drug

Δt
(11)
In (11), mD is the mass of the drug dose in mg,
mEq Li/mg drug is the conversion factor for lithium active
ingredient contained in each mg of drug, and Δt is the time
over which the constant rate absorption of the time-release
capsule occurs. According to [3], peak serum concentrations
occur4–12hoursafterdosingwithcontrolledreleaselithium
drug. Logically, this implies that the last of the lithium
drug is delivered to the system 4–12 hours after the dose
is administered. By utilizing the lower end of this range
of drug absorption time, a “worst-case” scenario for peak
tissueconcentrationwithatime-releasedrugregimenwillbe
obtained. Therefore, the default assumption for the duration
of drug absorption during administration was to use Δt = 4
hours in (11). The timing of the predicted peak in plasma
lithium concentration in the model that corresponds to this
G(t) is four hours, conﬁrming that the peak concentration
corresponds with the end of drug release and absorption in
our model.
Plasma (plasma compartment mass balance):
dCP
dt
=

QG
CG
RG
+QK
CK
RK
+QB
CB
RB
+QU
CU
RU
+QT
CT
RT
+QBr
CBr
RBr
−(QG+QK+QB+QU+QT +QBr)CP

1
VP
(12)
The mass balance on the plasma compartment includes the
sum of all the outﬂows from and inﬂows to each of the
individual compartments included in the model.
3. Results
All simulations were performed using the MATLAB software
suite.Inthemedicalliterature,bodilylithiumconcentrations
are reported in milliequivalents lithium/mL tissue volume
(mEq/mL); the unit mEq is equivalent to a millimol. In
this paper, we utilize the units mEq to report bodily
concentrations to be consistent with the medical literature.
Dosages of lithium drugs are reported in milligram of the
totaldrug,whichislithiumcarbonate(Li 2CO3)forthebrand
name drugs Eskolith and Lithobid. Therefore, for example, a
300mg tablet contains 8mEq lithium.
3.1. Lithium Concentration Proﬁles for a Single 900mg Dose
of Lithium Drug (as Li2CO3). A typical dosage regimen
for an individual suﬀering from bipolar disorder is to
administer 900mg of lithium drug twice daily. The lithium6 Advances in Bioinformatics
concentration time course (in mEq Li/mL) resulting from
a single 900mg dose of lithium drug, delivered via two
simultaneously administered 450mg controlled release cap-
sules, results in the concentration proﬁles shown in Figure 2.
The organs shown in Figure 2(b) are important for the aim
of this study, which was to provide better guidance for
safe lithium dosing for fetal development; the concentration
proﬁles shown in Figure 2(c) are other organs included in
the model but less critical for the aim of this study. The
d r u gr e l e a s eo c c u r so v e rf o u rh o u r s ,a sd e s c r i b e da b o v e ,i n
conjunction with the mass-balance development for the GI
Tract; after the last of the delivered drug has absorbed into
the system, all concentrations decay due to loss of lithium
through the urine via kidney clearance. Our simulation uses
a ﬂow rate of urine containing lithium of 20mL/minute; this
value is consistent with the standard accepted values of 20–
40mL/minute [3].
The concentration in each organ is based on the tissue
to plasma equilibrium distribution ratio, Ri.F o re x a m p l e ,
the concentration in the uterus is less than half that of the
plasma because the ratio for lithium partitioning into the
uterus from the plasma (RU)i s0 . 4[ 3].
These concentration proﬁles ﬁt the known data. There
is a peak in plasma lithium concentration at approximately
4hrs, concurrent with the end of drug dissolution from
the time-release capsule. The half-life of lithium can be
approximated as the time it takes for the lithium in the
plasma to decrease 50% from its maximum value. In our
model, this half-life is approximately 12 hours, which is
consistent with the reported serum half-life of lithium for
pregnant women [4].
3.2. Lithium Concentration Proﬁles for Dosage Regimens
Known to Cause Birth Defects. Lithium is known to cause
birth defects in infants; although there have been no clinical
trials to ascertain the exact dosage that causes harm. There
are, however, several reported cases of women who contin-
ued to take lithium during their pregnancy, gave birth to a
baby with birth defects, and the doctors reported the dosage
regimen. One-dosage regimen that has been documented to
cause birth defects was two capsules daily, 450mg in the
morning followed by 900mg in the evening [2]. There are
numerous sources, including the International Register of
Lithium Babies, that document birth defects as a result of
treatment with lithium. However, the dosage regimens used
are not reported or accessible. The standard dosage of two
900mg doses daily was used to describe the dosage proﬁles
for these cases. The predicted lithium concentrations over
time associated with these dosing regimens are shown in
Figure 3 for the brain, plasma, fetus, and the uterus.
For both dosage regimens, the ﬁgure shows the concen-
tration proﬁle after the patient has been taking the drug for
a long period of time; this means that every two-dose cycle
has the exact same proﬁle, which will be referred to as the
terminal proﬁle. The ﬁrst regimen with alternating dosage
sizes resulted in a concentration proﬁle of high and low
peaks. The maximum fetus concentration associated with
the 450mg/900mg regimen is 1.4mEq/mL, with an average
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Figure 2: Concentration proﬁles in all physiological compartments
resulting from a single, time-release 900mg dosage of lithium
drug. Initial lithium concentration in the body is 0mEq/mL.
(a) Proﬁle of drug release pulse. (b) Lithium concentration time
courses in the most important compartments for the study, with
fetus labeled. (c) Lithium concentration proﬁles for less critical
compartments.Advances in Bioinformatics 7
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Figure 3: Terminal concentration proﬁles in selected physiological compartments for dosage regimens that are known to cause birth defects.
In this case, lithium medication is administered twice daily and controlled-release tablets release lithium over 4 hours. A pulse function
corresponding to the drug absorption is shown above each ﬁgure. (a) One dose of a 450mg tablet (12mEq lithium) with a subsequent
900mg (24mEq lithium) dose. (b) Two doses of a 900mg tablet (24mEq lithium).
concentration of 0.97mEq/mL. For the second regimen of
two 900mg doses daily, the peak fetus concentration is
1.7mEq/mL and an average concentration of 1.3mEq/mL.
Both peaks and means were found using a terminal proﬁle.
Birth defects could be caused by either the maximum
concentration experienced by the fetus, or the average
concentration of lithium in the fetus over the gestation
period; the data presently available does not conclusively
point to either of these as the primary cause of the birth
deformations. While this information cannot be utilized to
recommend a “safe” dosage regimen that can guarantee a
defect-free fetus, there are two useful conclusions from these
results.
The ﬁrst and most useful output from this analysis is
to provide, from the 450mg/900mg dosage regimen, the
following concentrations which should not be exceeded
during lithium treatment of a pregnant woman:
(1) a maximum peak fetal lithium concentration,
(2) an average fetal lithium concentration.
These standards can be used to identify lithium therapy
regimens likely to exceed these known pathological concen-
trations,sothattheiradministrationtopregnantpatientscan
be prevented.
The second output is the ability to now use the model
to suggest dosage regimens that will result in fetal concen-
trations that fall signiﬁcantly below the known pathological
levels, while still maintain high enough concentrations to be
eﬀective for the mother; this is the topic of the next section.
3.3. Lithium Dosage Regimens Eliminated Based on Model
Results. The previously documented pathological cases are
primarily useful in ruling out other potential dosage regi-
mens. To this end, we selected two dosing regimens within
the therapeutic dose range where the eﬀect on the fetus
is unknown. The ﬁrst dosage regimen we modeled is two
700mg doses, 12hrs apart (denoted 700/700). The next
dosage regimen is a 1000mg dose followed by a 300mg dose
12hrs later. The results of these simulations are shown in
Figure 4.
The 700/700 dosage regimen gives a higher average con-
centration than the pathological dosage, while maintaining
a lower peak concentration. This is because the doses are
more “spread out” across the day. The 1000/300 dosage
regimen gives a higher peak than the pathological dosage,
while maintaining a lower average. Neither of these regimens
shouldbeconsideredforpregnantwomenbecausetheycross
the pathological dosage either average or peak concentration
and therefore have the potential to cause birth defects. The
power behind this conclusion is that the model used clinical8 Advances in Bioinformatics
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Figure 4: Model-predicted pathological dosage regimens. The
maximum and average fetus concentrations from the 450/900
dosage regimen are plotted along with two new dosage regimens.
A 300/1000 dosage regimen is shown in black and a 700/700 dosage
regimen is shown in blue.
pathological data to eliminate dosing regimens that have an
unknown/undocumented eﬀect on a fetus.
3.4. Model-Suggested Reduced Risk Lithium Dosage Regimens.
In order to ﬁnd safer dosage regimens, we modeled several
regimens to ﬁnd ones with peak and average concentrations
below the pathological dosage. Drug ingestion does not
have to occur only twice daily, and the regimens we tested
reﬂect this. However, we did not consider the eﬀect of
nonevenly spaced dosages which, due to its complexity and
questionable clinical relevance, is beyond the scope of the
current work. We modeled the following regimens: 300/300,
600/600, 300/300/500, 400/400/400, and 300/300/300/300
(allinmg).Weincludedthe300/300dosageregimenbecause
this has been suggested as an average lowest eﬀective dosage
regimen [2].Althoughthisvariesforeachpatient,itisagood
starting value for minimum eﬀective dose. The 300/300/500
dosage regimen simulates two low doses with breakfast
and lunch and a slightly higher dosage with dinner to go
through the night. Figure 5 show the results of several of
these simulations. Table 2 shows the maximum and average
concentration values of these dosage regimens.
All of the dosage regimens modeled show both a lower
peak concentration and average concentration than the
pathological dosage. We noticed several interesting aspects
when evaluating these simulations. First, fewer doses per day
give a higher peak concentration at constant daily dosage.
For example, the 600/600 regimen (not shown) has a peak
concentration of 1.141mEq/mL. The 400/400/400 regimen,
however,hasapeakconcentrationof1.019mEq/mL.Second,
higher peak concentrations do not necessarily mean a higher
average concentration. The data from the three 1200mg/day
dosages (300/300/300/300, 400/400/400, and 600/600) show
that predicting average fetus concentration from total
d o s a g e ,n u m b e ro fd o s e s ,o rp e a kf e t u sc o n c e n t r a t i o nc a nb e
diﬃcult or nonintuitive.
05 1 0 15 20
Time (hrs)
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
m
E
q
/
m
L
)
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Maximum fetal concentration value from pathological dosage
Average fetal concentration value from pathological dosage
300 mg/300 mg/500 mg dosage regime
400 mg/400 mg/400 mg dosage regime
300 mg/300 mg/300 mg/300 mg dosage regime
300 mg/300 mg dosage regime
Figure 5: Model-predicted reduced risk dosage regimens. The
maximum and average fetus concentrations from the 450/900
dosage regimen are plotted along with two new dosage regimens.
The values for average and peak concentrations are listed in Table 2.
Table 2: Average and maximum fetal concentrations (mEq/mL)for
suggesteddosageregimenscomparedwiththepathologicalcase.All
dosages are over a 24 hour period.
Dosage regimen
Average fetal
concentration
(mEq/mL)
Maximum
fetal
concentration
(mEq/mL)
450mg/900mg (pathological) 0.965 1.434
300mg/300mg/500mg 0.796 1.021
300mg/300mg 0.419 0.570
300mg/300mg/300mg/300mg 0.867 0.960
400mg/400mg/400mg 0.860 1.019
600mg/600mg 0.886 1.141
In order to ﬁnd a recommended maximum reduced
risk regimen, we need to consider both the peak and
average concentrations. All of the dosage regimens displayed
in Figure 5 show average and peak concentrations below
the pathological dosage; therefore, they are all acceptable
from a quantitative viewpoint. The “best” recommended
dosage regimens to reduce risk are the 300/300/300/300
and 400/400/400 regimens. The 300/300/300/300 regimen
is the best quantitatively. The average concentration is only
slightly less than the pathological dosage, but no peak goes
above the pathological dosage average. The downfall of this
dosage regimen, however, is that four doses per day may
be diﬃcult for patients to reasonably take. For compliant
patients who are concerned with the welfare of the child
and need high lithium dosages, the 300/300/300/300 dosage
regimen is the best maximum regimen. For any other
patient, a dosage regimen that allows for taking the drug
with meals will be much more convenient and likely to
succeed in a clinical setting. The best maximum regimenAdvances in Bioinformatics 9
for most patients will therefore be the 400/400/400 dosage
regimen. This regimen keeps the average concentration
slightly lower than the 300/300/300/300 regimen, and the
peaks in the concentration proﬁle go slightly above the
Pathological Dosage average concentration. However, since
only the peaks are higher than the pathological dosage
average concentration, there should still be reduced risk
associated with this dosing regimen. It should be noted that
thisbestdosageregimenwasdeterminedfromtheresultsofa
simulationwhichhasnotbeenvalidatedbyanimalorclinical
trials; furthermore the treatment of patients deals with
individuals. Because individuals respond to drugs diﬀerently
andhavemanydiﬀerentmedicalhistories,theoptimumdose
(and even the maximum safe dose) will vary with individual
patients. The results of this study should therefore be taken
as a guide to safely treat patients rather than universal canon.
4. Conclusion
This model has taken the ﬁrst steps toward predicting the
maximum acceptable lithium dosage regimen for pregnant
bipolar women. Based on our simulation results and on
clinical patient compliance, we recommend a maximum
dosage regimen of three doses of 400mg lithium evenly
spaced over a 24-hour period. It is important to note that
the maximum dosages recommended from the model are
not necessarily nonpathological. These recommended dose
regimens simply lower the average and peak values below
concentrations known to be pathological. It is still important
to take the lowest eﬀective dosage of lithium to minimize the
riskofbirthdefects.Hopefully,thispaperhasshedsomelight
on what the maximum doses in a dosage regimen should
look like to lower the risk of birth defects. Future research to
improve the model could include determination of the fetal
tissuetoplasmalithiumequilibriumratioandcollectingdata
on “safe” dosages of lithium that do not cause birth defects.
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